X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA SHASUN PHARMA PLETHICO PHARMA/
SHASUN PHARMA
 
P/E (TTM) x -1.1 123.9 - View Chart
P/BV x 0.0 8.5 0.2% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 PLETHICO PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
SHASUN PHARMA
Mar-14
PLETHICO PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs39594 419.2%   
Low Rs3146 68.6%   
Sales per share (Unadj.) Rs604.4214.2 282.2%  
Earnings per share (Unadj.) Rs32.55.3 608.7%  
Cash flow per share (Unadj.) Rs51.315.8 324.4%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %01.4 0.0%  
Book value per share (Unadj.) Rs473.653.3 887.8%  
Shares outstanding (eoy) m34.0856.62 60.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.40.3 108.0%   
Avg P/E ratio x6.613.1 50.1%  
P/CF ratio (eoy) x4.24.4 94.0%  
Price / Book Value ratio x0.51.3 34.3%  
Dividend payout %018.7 0.0%   
Avg Mkt Cap Rs m7,2623,958 183.5%   
No. of employees `000NANA-   
Total wages/salary Rs m1,5962,164 73.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m20,59812,127 169.9%  
Other income Rs m386229 168.4%   
Total revenues Rs m20,98412,356 169.8%   
Gross profit Rs m2,8181,009 279.2%  
Depreciation Rs m642594 108.2%   
Interest Rs m1,593415 383.8%   
Profit before tax Rs m969230 421.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138-73 190.3%   
Profit after tax Rs m1,107302 366.4%  
Gross profit margin %13.78.3 164.4%  
Effective tax rate %-14.3-31.7 45.1%   
Net profit margin %5.42.5 215.7%  
BALANCE SHEET DATA
Current assets Rs m18,8776,884 274.2%   
Current liabilities Rs m11,8968,456 140.7%   
Net working cap to sales %33.9-13.0 -261.5%  
Current ratio x1.60.8 194.9%  
Inventory Days Days3662 58.3%  
Debtors Days Days198108 183.9%  
Net fixed assets Rs m9,8614,970 198.4%   
Share capital Rs m341113 300.7%   
"Free" reserves Rs m12,3312,875 428.9%   
Net worth Rs m16,1393,020 534.4%   
Long term debt Rs m4,7061,817 258.9%   
Total assets Rs m33,14613,347 248.3%  
Interest coverage x1.61.6 103.5%   
Debt to equity ratio x0.30.6 48.5%  
Sales to assets ratio x0.60.9 68.4%   
Return on assets %8.15.4 151.6%  
Return on equity %6.910.0 68.6%  
Return on capital %12.313.3 92.2%  
Exports to sales %21.446.4 46.1%   
Imports to sales %15.214.2 106.9%   
Exports (fob) Rs m4,4025,622 78.3%   
Imports (cif) Rs m3,1361,728 181.5%   
Fx inflow Rs m4,4025,843 75.4%   
Fx outflow Rs m3,1842,173 146.5%   
Net fx Rs m1,2193,669 33.2%   
CASH FLOW
From Operations Rs m2,437398 613.0%  
From Investments Rs m-6,265-1,635 383.2%  
From Financial Activity Rs m2,4901,309 190.3%  
Net Cashflow Rs m-1,33771 -1,878.0%  

Share Holding

Indian Promoters % 82.7 39.2 211.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 3.6 119.4%  
FIIs % 5.5 17.6 31.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 39.6 18.9%  
Shareholders   10,665 20,750 51.4%  
Pledged promoter(s) holding % 85.7 12.3 697.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   CIPLA  PFIZER  ALKEM LABORATORIES  SUN PHARMA  SANOFI INDIA  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS